Biotech "Tweets of the Week" for February 2-6, 2015"Modest" discounts, you say?
|
|
Takes a special person to run a public company IMO. With push for bios to IPO last 2 years, expect many execs won't get it. Caveat emptor!
— PropThinker (@PropThinker) February 1, 2015
The saddest story Roald Dahl ever wrote — about his daughter’s death from measles — is worth reading http://t.co/L2pD1y6S4X
— Washington Post (@washingtonpost) February 2, 2015
Christie, who held captive a 100% healthy nurse returning from ebola work, says parents should feel free to let children spread contagion.
— Philip Gourevitch (@PGourevitch) February 2, 2015
Very difficult for this market to hold on to gains lately.
— Brad Loncar (@bradloncar) February 2, 2015
BTD is excellent, and highly relevant news for any program where the time to market is so unclear at the moment. $BLUE
— Brad Loncar (@bradloncar) February 2, 2015
$ESPR Partial clinical hold removed for ETC-1002
— Matthew Herper (@matthewherper) February 2, 2015
there are 5000 stocks you can own and at least 70 quality biotechs what attracts people to a pos like $HEB
— Dan Rosenblum (@sharkbiotech) February 3, 2015
When your press release has a Grand Caymans dateline, you're no longer pretending about taxes. $THRX
— Jon Gardner (@JonEPVantage) February 3, 2015
$VRX again...
— Bio Stocks™ (@BioStocks) February 3, 2015
$VRX $SLXP would be a match made in heaven...rather than vows, they'll exchange inventory and tax rate...roll it on up pearson
— zach (@zbiotech) February 3, 2015
@cbtadvisors @JacobEPVantage $BIIB 50% chance of approval for AD program by 2016 is an absolute joke. like elan analysts in 2007
— masterlongevity (@masterlongevity) February 3, 2015
$ESPR added more in the 48s
— Subramania Kaushik (@skaushi) February 3, 2015
$PFE palbo approved
— zach (@zbiotech) February 3, 2015
Here's a chart showing the relative value of CAR-T companies since $JUNO went public (my data): pic.twitter.com/97A9sgBGka
— Brad Loncar (@bradloncar) February 3, 2015
$gild whiplash
— DeadCatBill (@getbillasap) February 3, 2015
Gross to net discount is 46% for harvoni in 2015. $GILD Unless I misheard.
— David Sobek (@dsobek) February 3, 2015
$BLUE nice sign on the 5 min. Possible reversal taking shape. Needs the market to help though.
— BioBounce.com (@BioBounce) February 3, 2015
@zDonShimoda 2 hours ago, we were all waiting for $GILD to save entire sector. Sentiments change fast here. Ladies & gents, here's biotech.
— ohmsonite (@ohmsonite) February 3, 2015
Too bad $ABBV call was before $GILD call. Analysts would've had a lotta questions for ABBV on their discounts...
— Caroline Chen (@CarolineYLChen) February 3, 2015
No worries, $IBB will recover tomorrow now that $MNOV is on its way to become a NASH powerhouse
— Juan P. Serrate, DVM (@JPZaragoza1) February 3, 2015
$CTIC well, have institutions and traders discovered that TOP LINE PHASE 3 results are coming within a month? Looks to be setting up here
— Rick (@Skipjackrick) February 3, 2015
so we now see how $GILD managed to 'win' all those contracts
— zach (@zbiotech) February 4, 2015
2014=MoMo
2015=NoMo
— happycamper (@happyycamperr) February 4, 2015
.@Drchik23 FDA oncology BTD drugs being approved at amazing speed (Keytruda, Blincyto, Opdivo), just not that many from SMID bio, $CLVS next
— Andy Biotech (@AndyBiotech) February 4, 2015
$SRNE CFO resigned 1/30? They have data in a few weeks - this is no bueno
— Red Acre Investments (@redacre) February 3, 2015
$ZIOP prices 10m shares at $8.75/share
— Shane Blackmon (@shaneblackmon) February 3, 2015
@Qcn79 $IBB weekly chart show the indicators high in the over-bought territories & want a correction, let's wait for this week final candle
— Joe (@GantosJ) February 4, 2015
I'd love to see $RARE go mid-to-low $40s in a biotech slump, but this is definitely nibble territory.
— Brad Loncar (@bradloncar) February 4, 2015
@zDonShimoda Textbook 50 MA bounce so far $KITE
— DCam (@dcamtrades) February 4, 2015
Bought 100 shares of $KITE My biotech portfolio now composed of $ATHX, $OREX, $NVIV and $KITE
— vlad33301 (@vlad33301) February 4, 2015
$ZGNX out in full 4 small gains. Weak all day, #onceabioturdalwaysabioturd
— WiseRguy (@wiseRguy1971) February 4, 2015
$TKMR filed for delisting from TSX
— Zack (@BioTerp) February 4, 2015
@amitkjolly @DOGE4321 Probably twitter.
— V.S. Schulz (@portefeuillefun) February 4, 2015
$MBVX "selected" to present at BIOCEO15? //you mean "we paid the speaking fee" right?
— Red Acre Investments (@redacre) February 4, 2015
WF"Drugs in oncology and orphan diseases should be more immune to pricing pressure.Favorable long-term $CELG $BMRN $PCYC $VRTX $INCY $ALXN."
— Tom Silver (@TomSilver39) February 5, 2015
$ICPT offering priced at $176/share.
— Adam Feuerstein (@adamfeuerstein) February 5, 2015
Belgian Biotech up 25% since start of the year. Still undervalued. $ABLX $TIG $GTCL $MDXH $ARGX $GLPG $THR $CARD
— BioStockAddict (@BioStockAddict) February 5, 2015
Twitter and Google strike deal to show tweets in search results - $TWTR $GOOG #tech http://t.co/OEFhXqJk0K
— Bio Stocks™ (@BioStocks) February 5, 2015
$PFE Pfizer to acquire Hospira for $90 per share in cash, or approx. $17B.
— Chill Till (@ChillzTrading) February 5, 2015
RT @BioDueDiligence: Never seen this reason for a trial being suspended: overwhelming enrollment interest! https://t.co/0PwlzBWrLf $MDVN
— Adam Feuerstein (@adamfeuerstein) February 5, 2015
Wonder how Hamburg resignation will affect $BMRN $SRPT DMD accelerated approval applications
— j l (@lomu_j) February 5, 2015
$MNKD Seven dolla holla pre-market
— Chet Stedman (@ChetStedman5) February 5, 2015
Averaged up on $ENTA this a.m. Way too cheap
— Ross Anderson (@grdollasign) February 5, 2015
Glad I shaved that bio cursed beard last night
— Joshua B (@srqstockpicker) February 5, 2015
the fall in $AAVL has been swift. they just raised at $59 less than a month ago. crazy. may buy some here.
— Chris Ahlstrand (@ahlstrac) February 5, 2015
Bought 1k $aavl 33.04 joined @stocktilludrop on the buy
— Joshua B (@srqstockpicker) February 5, 2015
$VRX raises bid for $DNDN's Provenge to $400m (from $296m) due to competing offers
— Meg Tirrell (@megtirrell) February 5, 2015
Look at that rock solid floor @ 30.40 put in by $ACAD for a week. Now reversing higher and breaking descending trendline. #NUPLAZID
— CashRocket (@CashRocket) February 5, 2015
$WYY is in the business of protecting patients privacy and health records. https://t.co/Ll3yLpsz3K
— Brandon Hayward (@VexTrades) February 5, 2015
“@BlockTradeAlert: BLOCK TRADE: $ARIA 250,000 shares @ $6.72 [15:25:08]” what's cookin'?
— S Manian (@DrSManian) February 5, 2015
Get involved in the biosimilar market >> $EPRS or $CHRS or both. I think this will be a hot area in the coming years.
— Jason Napodano, CFA (@JNapodano) February 5, 2015
Worst day of year followed by best. This market is nuts.
— Festo (@Festo50) February 5, 2015
$DERM Announces Positive Ph.2B Results For DRM04 In Patients With Hyperhidrosis
— Bio Stocks™ (@BioStocks) February 5, 2015
So because we know the drug works we didn't power it for stat sig. That's logic $derm
— NathanAaron (@NathanAhron) February 5, 2015
Credit Suisse downgrades $GILD to neutral, lowers price target to $115 from $130 on hepatitis C outlook
— Meg Tirrell (@megtirrell) February 6, 2015
$ACAD 32.51
Initiated with a Buy, PT $42 -Roth
— Tom Wrigley (@WrigleyTom) February 6, 2015
$BMY FDA also intends to rescind BTD status for certain daclatasvir-containing regimens due to #HCV landscape changes. via @PinkSheetSutter
— Andy Biotech (@AndyBiotech) February 6, 2015
@adamfeuerstein in spite of bullish ABBV's CC comments, Street expects them 2 'show me the money' for that exact reason. So net negative IMO
— Raj R (@rajramaswamy) February 6, 2015
afrezza 14 NRx
— zach (@zbiotech) February 6, 2015
@bradloncar good point on $tril, and since they met w FDA last month on trial, they should have a clear roadmap
— jay arnold (@jayabacus) February 6, 2015
opco upgrades $IMGN, $8 of their $11 tgt attributed to '853
— zach (@zbiotech) February 6, 2015
Buy the dip: 25 Perma Bears: 0
— Bobby Shea (@robertcshea) February 6, 2015